OBJECTIVES: Cytochrome oxidase (COX) dysfunction is associated with mitochondrial oxidative stress. We determined the association between COX expression, obesity and type 2 diabetes. SUBJECTS/ METHODS: COX4I1 and COX10 genes were measured in monocytes of 24 lean controls, 31 glucose-tolerant and 67 diabetic obese patients, and 17 morbidly obese patients before and after bariatric surgery. We investigated the effect of caloric restriction and peroxisome proliferator-activated receptor (PPAR) agonist treatment on Cox in obese diabetic mice, and that of diet-induced insulin resistance in Streptozotocin-treated mice. RESULTS: Low COX4I1 was associated with type 2 diabetes in obese patients, adjusting for age, gender, smoking, interleukin-6 and high-sensitivity C-reactive protein, all related to metabolic syndrome (MetS; odds ratio: 6.1, 95% confidence interval: 2.3-16). In contrast, COX10 was low in glucose-tolerant and diabetic obese patients. In morbidly obese patients, COX4I1 was lower in visceral adipose tissue collected at bariatric surgery. In their monocytes, COX4I1 decreased after bariatric surgery, and low COX4I1 at 4 months was associated with MetS at 7 years. In leptin-deficient obese diabetic mice, Cox4i1 was low in white visceral adipose tissue (n=13; P<0.001) compared with age-matched lean mice (n=10). PPARγ-agonist treatment (n=13), but not caloric restriction (n=11), increased Cox4i1 (P<0.001). Increase in Cox4i1 depended on the increase in glucose transporter 4 (Glut4) expression and insulin sensitivity, independent of the increase in blood adiponectin. In streptozotocin-treated mice (three groups of seven mice, diet-induced insulin resistance decreased Cox4i1 and Glut4 (P<0.001 for both). CONCLUSION: COX4I1 depression is related to insulin resistance and type 2 diabetes in obesity. In peripheral blood monocytes, it may be a diagnostically useful biomarker.
OBJECTIVES:Cytochrome oxidase (COX) dysfunction is associated with mitochondrial oxidative stress. We determined the association between COX expression, obesity and type 2 diabetes. SUBJECTS/ METHODS:COX4I1 and COX10 genes were measured in monocytes of 24 lean controls, 31 glucose-tolerant and 67 diabetic obesepatients, and 17 morbidly obesepatients before and after bariatric surgery. We investigated the effect of caloric restriction and peroxisome proliferator-activated receptor (PPAR) agonist treatment on Cox in obese diabeticmice, and that of diet-induced insulin resistance in Streptozotocin-treated mice. RESULTS: Low COX4I1 was associated with type 2 diabetes in obesepatients, adjusting for age, gender, smoking, interleukin-6 and high-sensitivity C-reactive protein, all related to metabolic syndrome (MetS; odds ratio: 6.1, 95% confidence interval: 2.3-16). In contrast, COX10 was low in glucose-tolerant and diabetic obesepatients. In morbidly obesepatients, COX4I1 was lower in visceral adipose tissue collected at bariatric surgery. In their monocytes, COX4I1 decreased after bariatric surgery, and low COX4I1 at 4 months was associated with MetS at 7 years. In leptin-deficient obese diabeticmice, Cox4i1 was low in white visceral adipose tissue (n=13; P<0.001) compared with age-matched lean mice (n=10). PPARγ-agonist treatment (n=13), but not caloric restriction (n=11), increased Cox4i1 (P<0.001). Increase in Cox4i1 depended on the increase in glucose transporter 4 (Glut4) expression and insulin sensitivity, independent of the increase in blood adiponectin. In streptozotocin-treated mice (three groups of seven mice, diet-induced insulin resistance decreased Cox4i1 and Glut4 (P<0.001 for both). CONCLUSION:COX4I1 depression is related to insulin resistance and type 2 diabetes in obesity. In peripheral blood monocytes, it may be a diagnostically useful biomarker.
Authors: W F Pickl; O Majdic; P Kohl; J Stöckl; E Riedl; C Scheinecker; C Bello-Fernandez; W Knapp Journal: J Immunol Date: 1996-11-01 Impact factor: 5.422
Authors: Eileen M Burkart; Nandakumar Sambandam; Xianlin Han; Richard W Gross; Michael Courtois; Carolyn M Gierasch; Kooresh Shoghi; Michael J Welch; Daniel P Kelly Journal: J Clin Invest Date: 2007-12 Impact factor: 14.808
Authors: Ying Liu; Rengasamy Palanivel; Esther Rai; Min Park; Tim V Gabor; Michael P Scheid; Aimin Xu; Gary Sweeney Journal: Diabetes Date: 2014-07-28 Impact factor: 9.461
Authors: Paul Holvoet; Stephen B Kritchevsky; Russell P Tracy; Ann Mertens; Susan M Rubin; Javed Butler; Bret Goodpaster; Tamara B Harris Journal: Diabetes Date: 2004-04 Impact factor: 9.461
Authors: Jo Vandesompele; Katleen De Preter; Filip Pattyn; Bruce Poppe; Nadine Van Roy; Anne De Paepe; Frank Speleman Journal: Genome Biol Date: 2002-06-18 Impact factor: 13.583
Authors: Chuan Li; Antoine Menoret; Cullen Farragher; Zhengqing Ouyang; Christopher Bonin; Paul Holvoet; Anthony T Vella; Beiyan Zhou Journal: JCI Insight Date: 2019-04-16
Authors: Yongxin Li; Yu Meng; Xiangyang Zhu; Andre Van Wijnen; Alfonso Eirin; Lilach O Lerman Journal: Front Endocrinol (Lausanne) Date: 2021-08-12 Impact factor: 5.555
Authors: Paul Holvoet; Maarten Vanhaverbeke; Katarzyna Bloch; Pieter Baatsen; Peter Sinnaeve; Stefan Janssens Journal: J Am Heart Assoc Date: 2016-12-05 Impact factor: 5.501
Authors: Eugene Nyamugenda; Haven Griffin; Susan Russell; Kimberly A Cooney; Nicholas S Kowalczyk; Ishrar Islam; Kevin D Phelan; Giulia Baldini Journal: iScience Date: 2020-05-01
Authors: Lei Wu; Xin Guo; Yi Lyu; Stephen L Clarke; Edralin A Lucas; Brenda J Smith; Deana Hildebrand; Weiqun Wang; Denis M Medeiros; Xinchun Shen; Dingbo Lin Journal: Sci Rep Date: 2017-11-07 Impact factor: 4.379